ACMR experienced a dramatic operational deterioration with operating cash flow swinging from +$152.4M to -$10.3M while simultaneously showing unusual balance sheet strength through an 86% cash increase and 105% revenue growth.
The stark contradiction between collapsing operating cash flow and massive cash growth suggests either significant non-operating cash inflows (potentially equity raises or debt financing) or unusual working capital dynamics that merit immediate investor scrutiny. The 107% operating cash flow decline combined with 38% R&D expense increases indicates the company is burning cash operationally while investing heavily in growth, creating execution risk despite apparent financial resources.
ACMR shows a tale of two balance sheets - while revenue doubled (+105%) and cash nearly doubled (+86%), operating cash flow collapsed from +$152M to -$10M, representing a 107% deterioration in core cash generation. The company simultaneously strengthened its balance sheet with 62% equity growth and 55% total asset expansion while increasing debt 43% and R&D spending 38%, suggesting aggressive growth investments funded through external capital rather than operational performance. This financial profile indicates a company in rapid expansion mode but with concerning operational cash burn that could pressure future performance if growth investments don't materialize into sustained profitability.
Operating cash flow fell 106.8% — earnings quality concerns; investigate working capital changes and non-cash items.
Strong top-line growth of 104.5% — accelerating demand or successful expansion into new markets.
Cash position surged 85.9% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 64.3% — improving short-term liquidity or inventory/receivables build.
Interest expense surged 62% — significant debt increase or rising rates materially impacting earnings.
Equity base grew 61.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 54.8% — expansion through organic growth, acquisitions, or capital deployment.
Debt increased 42.7% — substantial leverage increase; assess whether deployed for growth or covering losses.
R&D investment increased 37.5% — signals commitment to future product development, though near-term margin impact.
Capex reduced 31.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →